Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY26 results · Jul–Sep 2025
Lincoln Pharmaceuticals reported revenue from operations of ₹163.36 crore (up 1.3% from Q2 FY25) and net profit of ₹19.98 crore (down 24.1% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.36 | 161.21 | +1.3% | 154.07 | +6.0% |
| Other income | 7.23 | 9.98 | −27.5% | 15.27 | −52.6% |
| Total income | 170.60 | 171.19 | −0.3% | 169.34 | +0.7% |
| Profit before tax | 28.81 | 34.78 | −17.2% | 35.39 | −18.6% |
| Net profit for the period | 19.98 | 26.33 | −24.1% | 27.68 | −27.8% |
| EPS, basic (₹) | 9.98 | 13.15 | −24.1% | 13.82 | −27.8% |
| Net margin (%) | 12.2 | 16.3 | 18.0 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.36 | 161.21 | +1.3% | 154.07 | +6.0% |
| Other income | 7.23 | 9.98 | −27.5% | 15.27 | −52.6% |
| Total income | 170.60 | 171.19 | −0.3% | 169.34 | +0.7% |
| Profit before tax | 28.81 | 34.78 | −17.2% | 35.39 | −18.6% |
| Net profit for the period | 19.98 | 26.33 | −24.1% | 27.68 | −27.8% |
| EPS, basic (₹) | 9.98 | 13.15 | −24.1% | 13.82 | −27.8% |
| Net margin (%) | 12.2 | 16.3 | 18.0 |
Consolidated
- Filed with BSE
- 13 Nov 2025, 17:41 IST
- Board meeting
- 13 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2025, 17:41 IST
- Board meeting
- 13 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE